SOURCE: MMIT Analytics, as of
4/22/19
Tuesday, April 23, 2019
Novartis' generic unit Sandoz has sued...
...United Therapeutics for what it
calls anticompetitive behavior over its copies of United's Remodulin. Novartis
says United placed "artificial restrictions" on cartridges needed for
intravenous delivery of the pulmonary arterial hypertension drug. In the
pharmacy benefit, Remodulin holds preferred-tier access for 10% of covered
lives, and is not covered for 19% of lives.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment